TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo

STAT3 operates in both cancer cells and tumor-associated immune cells to promote cancer progression. As a transcription factor, it is a highly desirable but difficult target for pharmacologic inhibition. We have recently shown that the TLR9 agonists CpG oligonucleotides can be used for targeted siRN...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2013-02, Vol.121 (8), p.1304-1315
Hauptverfasser:	Zhang, Qifang, Hossain, Dewan Md Sakib, Nechaev, Sergey, Kozlowska, Anna, Zhang, Wang, Liu, Yong, Kowolik, Claudia M., Swiderski, Piotr, Rossi, John J., Forman, Stephen, Pal, Sumanta, Bhatia, Ravi, Raubitschek, Andrew, Yu, Hua, Kortylewski, Marcin
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cell Line, Tumor Gene Therapy Gene Transfer Techniques Genetic Therapy - methods Hematologic Neoplasms - genetics Hematologic Neoplasms - therapy Hematopoietic Stem Cells - pathology Hematopoietic Stem Cells - physiology Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - therapy Lymphoma - genetics Lymphoma - therapy Mice Mice, Inbred BALB C Mice, Inbred NOD Mice, Knockout Mice, SCID Multiple Myeloma - genetics Multiple Myeloma - therapy Neoplasm Transplantation Oligodeoxyribonucleotides - genetics Radiotherapy RNA, Small Interfering - genetics RNA, Small Interfering - pharmacokinetics STAT3 Transcription Factor - genetics Toll-Like Receptor 9 - genetics Toll-Like Receptor 9 - metabolism Transplantation, Heterologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!